AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On March22, 2017, AVEO Pharmaceuticals, Inc. (the Company) issued
a press release announcing its financial results for the fiscal
year ended December31, 2016. The full text of the press release
issued in connection with the announcement is furnished as
Exhibit99.1 to this Current Report on Form 8-K.
The information in this Item2.02 of this Form 8-K and Exhibit
99.1 shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 99.1 |
Fiscal year 2016 earnings press release issued by the Company on March22, 2017 |
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15). AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Recent Trading Information
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) closed its last trading session 00.000 at 0.840 with 189,752 shares trading hands.